Allele-Specific MicroRNA-Mediated Regulation of a Glycolysis Gatekeeper PDK1 in Cancer Metabolism.

PDK1 metabolic reprogramming microRNAs single-nucleotide polymorphisms

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
17 Jul 2021
Historique:
received: 28 05 2021
revised: 09 07 2021
accepted: 13 07 2021
entrez: 24 7 2021
pubmed: 25 7 2021
medline: 25 7 2021
Statut: epublish

Résumé

Emerging evidence has revealed that genetic variations in microRNA (miRNA) binding sites called miRSNPs can alter miRNA binding in an allele-specific manner and impart prostate cancer (PCa) risk. Two miRSNPs, rs1530865 (G > C) and rs2357637 (C > A), in the 3' untranslated region of pyruvate dehydrogenase kinase 1 (PDK1) have been previously reported to be associated with PCa risk. However, these results have not been functionally validated. In silico analysis was used to predict miRNA-PDK1 interactions and was tested using PDK1 knockdown, miRNA overexpression and reporter gene assay. PDK1 expression was found to be upregulated in PCa metastasis. Further, our results show that PDK1 suppression reduced the migration, invasion, and glycolysis of PCa cells. Computational predictions showed that miR-3916, miR-3125 and miR-3928 had a higher binding affinity for the C allele than the G allele for the rs1530865 miRSNP which was validated by reporter gene assays. Similarly, miR-2116 and miR-889 had a higher affinity for the A than C allele of the rs2357637 miRSNP. Overexpression of miR-3916 and miR-3125 decreased PDK1 protein levels in cells expressing the rs1530865 SNP C allele, and miR-2116 reduced in cells with the rs2357637 SNP A allele. The present study is the first to report the regulation of the PDK1 gene by miRNAs in an allele-dependent manner and highlights the role of PDK1 in metabolic adaption associated with PCa progression.

Sections du résumé

BACKGROUND BACKGROUND
Emerging evidence has revealed that genetic variations in microRNA (miRNA) binding sites called miRSNPs can alter miRNA binding in an allele-specific manner and impart prostate cancer (PCa) risk. Two miRSNPs, rs1530865 (G > C) and rs2357637 (C > A), in the 3' untranslated region of pyruvate dehydrogenase kinase 1 (PDK1) have been previously reported to be associated with PCa risk. However, these results have not been functionally validated.
METHODS METHODS
In silico analysis was used to predict miRNA-PDK1 interactions and was tested using PDK1 knockdown, miRNA overexpression and reporter gene assay.
RESULTS RESULTS
PDK1 expression was found to be upregulated in PCa metastasis. Further, our results show that PDK1 suppression reduced the migration, invasion, and glycolysis of PCa cells. Computational predictions showed that miR-3916, miR-3125 and miR-3928 had a higher binding affinity for the C allele than the G allele for the rs1530865 miRSNP which was validated by reporter gene assays. Similarly, miR-2116 and miR-889 had a higher affinity for the A than C allele of the rs2357637 miRSNP. Overexpression of miR-3916 and miR-3125 decreased PDK1 protein levels in cells expressing the rs1530865 SNP C allele, and miR-2116 reduced in cells with the rs2357637 SNP A allele.
CONCLUSIONS CONCLUSIONS
The present study is the first to report the regulation of the PDK1 gene by miRNAs in an allele-dependent manner and highlights the role of PDK1 in metabolic adaption associated with PCa progression.

Identifiants

pubmed: 34298795
pii: cancers13143582
doi: 10.3390/cancers13143582
pmc: PMC8304593
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Cancer Council Queensland
ID : APP1121136

Références

Neoplasia. 2005 Jan;7(1):1-6
pubmed: 15736311
Prostate. 2017 Jun;77(9):1000-1011
pubmed: 28422308
Front Physiol. 2017 Feb 21;8:97
pubmed: 28270771
Oncol Lett. 2012 Oct;4(4):817-823
pubmed: 23205106
Nat Commun. 2016 May 18;7:11635
pubmed: 27189088
Invest Ophthalmol Vis Sci. 2016 Aug 1;57(10):4205-12
pubmed: 27548891
Front Oncol. 2019 Dec 11;9:1404
pubmed: 31921661
PLoS One. 2017 Nov 14;12(11):e0188090
pubmed: 29136645
Cell Rep. 2019 Apr 2;27(1):226-237.e4
pubmed: 30943404
J Pathol. 2015 Aug;236(4):517-30
pubmed: 25875424
J Cancer. 2020 Jan 1;11(4):962-973
pubmed: 31949499
Nat Commun. 2014 Oct 10;5:5212
pubmed: 25301052
Trends Cancer. 2017 Jun;3(6):391-406
pubmed: 28670628
Noncoding RNA. 2019 Mar 20;5(1):
pubmed: 30897768
Clin Chem. 2019 Sep;65(9):1090-1101
pubmed: 31101638
Oncogene. 2015 May 28;34(22):2846-55
pubmed: 25065599
Oncogene. 2018 Feb 22;37(8):1119
pubmed: 29251717
Nat Rev Cancer. 2004 Nov;4(11):891-9
pubmed: 15516961
Cancer Discov. 2015 Apr;5(4):368-79
pubmed: 25691096
Clin Chem. 2019 Jun;65(6):771-780
pubmed: 31018918
Anim Cells Syst (Seoul). 2020 Jun 25;24(4):220-227
pubmed: 33029299
FASEB J. 2017 Oct;31(10):4265-4276
pubmed: 28596235
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Cell Metab. 2018 May 01;27(5):977-987.e4
pubmed: 29628419
Oncol Rep. 2017 Jan;37(1):193-200
pubmed: 27878287
Neoplasma. 2018 Dec 10;66(1):63-72
pubmed: 30509100
Clin Chem. 2016 Oct;62(10):1318-33
pubmed: 27540032
Theranostics. 2020 Mar 26;10(11):4762-4778
pubmed: 32308748
Front Oncol. 2016 Nov 09;6:225
pubmed: 27882307
Clin Epigenetics. 2019 Feb 11;11(1):25
pubmed: 30744689
PLoS One. 2017 May 15;12(5):e0177744
pubmed: 28505181
R Soc Open Sci. 2017 Oct 25;4(10):170360
pubmed: 29134060
Theranostics. 2019 May 9;9(10):2999-3013
pubmed: 31244938
Anticancer Agents Med Chem. 2017;17(2):164-170
pubmed: 27804847
Autophagy. 2021 Mar;17(3):723-742
pubmed: 32186433
Cell Death Dis. 2019 Jan 17;10(2):40
pubmed: 30674873
Cancer Manag Res. 2018 Dec 24;11:251-262
pubmed: 30636897
Endocr Relat Cancer. 2019 Jan 1;26(1):59-71
pubmed: 30400006
Front Oncol. 2020 Mar 18;10:231
pubmed: 32257942
Int J Oncol. 2013 Jan;42(1):44-54
pubmed: 23135628
J Cell Physiol. 2019 May;234(5):6361-6370
pubmed: 30229902
Oncogenesis. 2020 Feb 18;9(2):24
pubmed: 32071289
Biochim Biophys Acta. 2009 Dec;1787(12):1433-43
pubmed: 19524545
Br J Cancer. 2020 Apr;122(9):1298-1308
pubmed: 32152504
Nat Commun. 2020 Apr 20;11(1):1869
pubmed: 32313017
Cell Metab. 2006 Mar;3(3):177-85
pubmed: 16517405

Auteurs

Sugarniya Subramaniam (S)

School of Biomedical Sciences, Faculty of Health, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane 4000, Australia.
Australian Prostate Cancer Research Centre-Queensland (APCRC-Q), Translational Research Institute, Queensland University of Technology, Woolloongabba 4102, Australia.

Varinder Jeet (V)

School of Biomedical Sciences, Faculty of Health, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane 4000, Australia.
Australian Prostate Cancer Research Centre-Queensland (APCRC-Q), Translational Research Institute, Queensland University of Technology, Woolloongabba 4102, Australia.

Jennifer H Gunter (JH)

School of Biomedical Sciences, Faculty of Health, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane 4000, Australia.
Australian Prostate Cancer Research Centre-Queensland (APCRC-Q), Translational Research Institute, Queensland University of Technology, Woolloongabba 4102, Australia.

Judith A Clements (JA)

School of Biomedical Sciences, Faculty of Health, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane 4000, Australia.
Australian Prostate Cancer Research Centre-Queensland (APCRC-Q), Translational Research Institute, Queensland University of Technology, Woolloongabba 4102, Australia.

Jyotsna Batra (J)

School of Biomedical Sciences, Faculty of Health, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane 4000, Australia.
Australian Prostate Cancer Research Centre-Queensland (APCRC-Q), Translational Research Institute, Queensland University of Technology, Woolloongabba 4102, Australia.

Classifications MeSH